The potential benefits of genetic testing in breast and ovarian cancer

Saudi Medical Journal

Volumn 20, Issue 9, 1999, Pages 663-670

  El Harith, El Harith A ^a   Abdel Hadi, Maha S ^b   Doerti, Thilo ^c   Badr, Ahmed N ^c   Schmidlke, Joerg ^c  

^a Institute of Human Genetics

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Breast ovarian cancers; Molecular testing

Indexed keywords

EID: 0009774399     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Bailey & Love's. Short Practice of Surgery. 21st ed. London-(UK): Chapmann Hall Medical; 1992. p. 788-821.
2. Akkad SM, Amer MH, Lin GS, Sabbah RS, Godwin JT. Pattern of cancer in Saudi Arabs referred to King Faisal Specialist Hospital. Cancer 1986; 58(5): 1172-1178.
3. Lynch HT, Marcus JN, Watson P, Conway T, Fitzsimmons ML, Lyncj JF. Genetic epidemiology of breast cancer. In: Lynch HT, Hirayama T editors. Genetic epidemiology of cancer. Boca Raton, Florida: CRC Press; 1989. p. 289-332.
4. Posner MC, Wolmark N. Indications of breast-preserving surgery and adjuvant therapy in early breast cancer. Int Surg 1994; 79: 43-47.
5. KelseyJL. Breast cancer. Epidemiol Rev 1993; 15: 17-168.
6. Muir CS, Donn AS. Breast cancer: epidemiology and risk factors. In: Khogali M, Omar YT, Gjorgov A, Ismail AS, editors. Cancer Prevention in Developing Countries. London (UK): Pergamon Press; 1986. p. 155-166.
7. Omar YT, Gjorgov A, Ismail AS, Tabik MA. Cancer trends in Kuwait (1974-1982). In: Khogali M, Omar YT, Gjorgov A, Ismail AS, editors. Cancer Prevention in Developing Countries. London (UK): Pergamon Press; 1986. p. 25-34.
8. Al-Fuadi A, Parkin DM. Cancer in Iraq: seven-year data from the Baghdad tumor registry. In: Khogali M, Omar YT, Gjorgov A, Ismail AS, editors. Cancer Prevention in Developing Countries. London (UK): Pergamon Press; 1986. p. 35-44.
9. Ibrahim AS. Site distribution of cancer in Egypt: twelve-year experience (1970-1981). In: Khogali M, Omar YT, Gjorgov A, Ismail AS, editors. Cancer Prevention in Developing Countries. London (UK): Pergamon Press; 1986. p. 45-50.
10. Birch JM, Hartley AL, Tricker KJ, Presser J, Condie A, Kesley AM et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994; 54: 1298-1304.
11. Malkin D, Li FP, Strong LC, Fraumeni JF Jr., Nelson CE, Kim DH et al. Germ-line p53 mutations in a familial syndrome of breast cancer sarcomas and other neoplasm. Science 1990; 250: 1233-1238.
12. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
13. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-1836.
14. Wooster R, Ford D, Mangion J, Ponder BA, Peto J, Easton DF et al. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. Hum Genet 1993; 92: 91-94.
15. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K. Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
16. Wooster R, Bignell G, Lancaster J, Swift S, Seal S. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
17. Tavtigian SV, Simard J, Romens J, Couch F, ShattuchEidens D, Neuhausen S et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12: 333-337.
18. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995; 72: 805-812.
19. Weber W. Update on breast cancer susceptibility genes. American Society of Clinical Oncology 34th Annual Meeting; 1998 May 16-19, 1998; Los Angeles (USA). In the educational book: "Inherited Breast Cancer Susceptibility and Testing Prevention", p. 242-248.
20. Easton DF, Bishop DT, Ford D, Crockford GP. The Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer; results from 214 families. Am J Hum Genet 1993; 52: 678-701.
21. Streuwing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
22. Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributed to BRCA1 or BRCA2. Am J Hum Genet 1997; 60: 1031-1040.
23. Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Molec Genet 1997; 6: 2309-2315.
24. Easton DF, Narod SA, Ford D, Steel M. The genetic epidemiology of BRCA1. Lancet 1994; 344: 761.
25. Meindl A, Golla A. Molekulargenetische Diagnostik bei Brustkrebs: Neuste Ergebnisse und Auswirkungen auf die genetische Beratung. Med Genet 1998; 10: 250-251.
26. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994; 12: 843-850.
27. Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 1995; 57: 385-392.
28. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Camonero A, Bonney G et al. BRCA1 testing in families with hereditary breast cancer-ovarian cancer. JAMA 1996; 275: 1885-1892.
29. Streuvving JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11: 198-200.
30. Streuwing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995; 57: 1-7.
31. American Society of Human Genetics. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1994;55:i-iv.
32. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA; 271: 785.
33. Richards CS, Ward PA, Rao BB, Friedman LC, Boyd AA, Kuenzli G et al. Screening for 185delAG in the Ashkenazim. Am J Hum Genet 1997; 60: 1085-1097.
34. Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45: 1437-1443.
35. Ottman R, Pike MC, King MC, Casagrande JT, Henderson BE. Familial breast cancer in a population-based series. Am J Epidemiol 1986; 123: 15-21.
36. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996; 13: 123-125.
37. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish woman affected by breast cancer. Nat Genet 1996; 13: 126-128.
38. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13: 120122.
39. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C et al. BRCA2 mutations in preliminary breast and ovarian cancers. Nat Genet 1996; 13: 238-240.
40. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996; 13: 245-247.
41. Teng DHF, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S et al. Low incidence of BRCA2 in breast carcinoma and other cancers. Nat Genet 1996; 13:241-244.
42. Takahashi H, Chiu HC, Bandera ÇA, Beehbakht K, Lin PC, Couch FJ et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996; 56: 2738-2741.
43. Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, Peyrat JP, Kerangueven F, Janin N et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancer. Cancer Res 1996; 56: 3126-3129.
44. Merajver SD, Pham TM, Caduff RF, Chen M, Cooney KA, Weber BL et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Nat Genet 1995; 9:439-443.
45. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G et al. A somatic BRCA1 mutation in an ovarian tumor. Nat Genet 1995; 9: 343-344.
46. Takahashi H, Behbakht K, McGovern PE, Chiu FJ, Weber BL, Friedman LS et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995; 55: 2998-3002.
47. Tonin P, Serova O, Lenoir G, Lynch H, Durocher F, Simard J et la. BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 1995; 57: 189.
48. Rao 'BE, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequency for common mutations in BRCA1 andBRCA2. Nat Genet 1996; 14: 185-187.
49. Tonin P, Weber B, Offit K, Couch F, Rebbeck T, Neuhausen S et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996; 2: 1179-1183.
50. Abeliovich D, Kaduri L, Lerer L, Weinberg N, Amir G, Sagi M et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997; 60: 505-514.
51. Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR et al. Assessment and counseling for women with a family history of breast cancer. JAMA 1995; 273: 577-585.
52. Lakhani SR, Easton DF, Stratton MR, Storfer-Isser A, Anderson TJ, Fand LM et al. Pathology of familial breast cancer: evidence for differences between breast cancers in carriers of BRCA1 or BRCA2 mutations, and sporadic cases. Lancet 1997; 349: 1505-1510.
53. Streuwing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Trucker MA. Prophylactic oophorectomy in inherited breast/ ovarian cancer families. J Natl Cancer Inst 1995; 17: 33-35.
54. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal cancinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer 1993; 71: 2751-2755.
55. El-Hazmi MAP, Al-Swailem AR, Warsy AS, Al-Swailem AM, Sulaimani R, AI-Mersi AA. Consanguinity in different regions of Saudi Arabia. J Med Genet 1995; 32: 623-626.
56. Taylor JW. Cancer in Saudi Arabia. Cancer 1963; 16: 1530-1536.
57. Gelpi AP. Malignant lymphoma in the Saudi Arab. Cancer 1970; 25: 892-895.
58. Perrine RP, Jumaa A. Changing trends in cancer in Saudi Arabia. Epidem Bull 1975.
59. Stirling GA, Khalil AM, Nada GN, Saad AA, Raheem MA. Study of one thousand consecutive malignant neoplasms in Saudis. Saudi Med J 1979; 1: 89-94.
60. Amer MH. Pattern of cancer in Saudi Arabia: a personal experience based on the management of 1, 000 patients. King Faisal Specialist Hospital Med J 1982; 2 (4): 203-215.
61. El-Akkad SM, Amer HM, Lin GS, Sabbah RS, Godwin JT. Pattern of cancer in Saudi Arabia referred to King Faisal Specialist Hospital. Cancer 1986; 58: 1172-1178.
62. Koreish OM, Al-Kuhaymi R. Cancer in Saudi Arabia: Riyadh Al-Kharji Hospital Programme experience. Saudi Med J 1984; 5: 217-223.
63. National Cancer Registry 1994 Report: "Cancer Incidence in Saudi Arabia 1994". Ministry of Health - May 1996 -Kindom of Saudi Arabia.
64. Mahboubi E. Epidemiology of cancer in Saudi Arabia, 1975-1985. Annals Saudi Medicine 1987; 7 (4): 265-276.
65. The 1987 Annual Report of the Tumor registry. King Faisal Specialist Hospital & Research Center.
66. Ibrahim EM. Pattern and Prognosis of breast cancer at a referral center in Saudi Arabia. Breast Disease 1990; 3: 187-198.
67. Al-Tamimi TM, Ibrahim EM, Ibrahim AM, AI-Bar AA, Assuhaimi SA, Gabriel GS et al. Breast cancer in the Eastern Region of Saudi Arabia: a population-based study (1987-1988). Annals of Saudi Medicine 1997; 17: 53-65.
68. Saudi Aramco Medical Services Organization (SAMSO). Annual report of the tumor registry. The Epidemiology Bulletin 1995; 34: 181-224.
69. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P et al. Hereditary breast cancer: pathology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996:77:697-709.
70. SEER Summary Stage (Cancer Surveillance Epidemiology and End Results Reporting). April Manual 1977.
71. UNICEF Report. The state of the world's children 1998. New York Oxford University Press, p. 122.